Clinical Trials Sponsored by F-star Therapeutics, Inc.

Total 7 results

F-star Therapeutics, Inc.

Completed

A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV (ACHIEVE)

Hepatitis B | Hepatitis, Viral

Canada, Hong Kong, Korea, Republic of, Taiwan
Syneos Health
F-star Therapeutics, Inc.

Completed

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Hepatitis C Infection

Australia, New Zealand
Gilead Sciences
F-star Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Chronic Hepatitis B

Korea, Republic of, Hong Kong
F-star Therapeutics, Inc.
PRA Health Sciences

Completed

A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

Drug Interaction Potentiation

Netherlands
F-star Therapeutics, Inc.
PRA Health Sciences

Terminated

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Hepatitis B | Hepatitis B, Chronic | HBV

Hong Kong
F-star Therapeutics, Inc.
PRA Health Sciences

Terminated

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Hepatitis B | Hepatitis B, Chronic | HBV

Canada, United Kingdom
F-star Therapeutics, Inc.
CSI Medical Research Pte Ltd

Terminated

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Hepatitis B | Hepatitis B, Chronic | HBV

Singapore

3

Subscribe